EA201691053A1 - Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии - Google Patents
Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапииInfo
- Publication number
- EA201691053A1 EA201691053A1 EA201691053A EA201691053A EA201691053A1 EA 201691053 A1 EA201691053 A1 EA 201691053A1 EA 201691053 A EA201691053 A EA 201691053A EA 201691053 A EA201691053 A EA 201691053A EA 201691053 A1 EA201691053 A1 EA 201691053A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- receptor
- fgfr3
- factor
- conjugates
- growth factor
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Согласно настоящему изобретению предложены конъюгаты, состоящие из лекарственного компонента и связывающегося с клеткой агента, которые целенаправленно воздействуют на рецептор фактора роста фибробластов 3 типа (FGFR3). Указанные конъюгаты имеют терапевтическое применение, поскольку они разработаны и специально созданы для целенаправленного воздействия на специфическую клеточную популяцию и для доставки сильного цитотоксина внутрь клетки. Конъюгат согласно настоящему изобретению обладает значительными преимуществами перед другими конъюгатами, известными в данной области техники, обеспечивая направленную терапию опухоли, а также существование "эффекта свидетеля" по отношению к соседним клеткам, на основании важного для онкологии рецептора, который экспрессируется только лишь на среднем уровне.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361917457P | 2013-12-18 | 2013-12-18 | |
US201461928025P | 2014-01-16 | 2014-01-16 | |
PCT/US2014/069720 WO2015094900A1 (en) | 2013-12-18 | 2014-12-11 | Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201691053A1 true EA201691053A1 (ru) | 2016-11-30 |
Family
ID=52282939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691053A EA201691053A1 (ru) | 2013-12-18 | 2014-12-11 | Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии |
Country Status (21)
Country | Link |
---|---|
US (1) | US9375488B2 (ru) |
EP (1) | EP3082873A1 (ru) |
JP (1) | JP6113933B1 (ru) |
KR (1) | KR101708603B1 (ru) |
CN (1) | CN105916523A (ru) |
AP (1) | AP2016009271A0 (ru) |
AU (1) | AU2014366359A1 (ru) |
BR (1) | BR112016013026A2 (ru) |
CA (1) | CA2930599A1 (ru) |
CL (1) | CL2016001496A1 (ru) |
EA (1) | EA201691053A1 (ru) |
HK (1) | HK1224179A1 (ru) |
IL (1) | IL245483A0 (ru) |
MX (1) | MX2016008072A (ru) |
NZ (1) | NZ719936A (ru) |
PE (1) | PE20160994A1 (ru) |
PH (1) | PH12016501185A1 (ru) |
SG (1) | SG11201604119YA (ru) |
TN (1) | TN2016000204A1 (ru) |
TW (1) | TWI541022B (ru) |
WO (1) | WO2015094900A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ594339A (en) | 2009-03-25 | 2013-06-28 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
TW201711702A (zh) * | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
UA126388C2 (uk) | 2016-11-18 | 2022-09-28 | Астеллас Фарма Інк. | Fab-фрагмент антитіла до muc1 людини |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
JP7374544B2 (ja) * | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物 |
AR123306A1 (es) | 2020-08-21 | 2022-11-16 | Genzyme Corp | Anticuerpos fgfr3 y métodos de uso |
WO2024107759A2 (en) * | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US7432088B2 (en) | 2003-05-08 | 2008-10-07 | Immunogen Inc. | Methods for the production of ansamitocins |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
EA012621B1 (ru) * | 2003-11-07 | 2009-10-30 | Чирон Корпорейшн | Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами |
US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
EP1913002B9 (en) | 2005-08-09 | 2012-04-25 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
ATE540956T1 (de) | 2005-11-08 | 2012-01-15 | Immunogen Inc | Verfahren zur herstellung von maytansinol |
SG189811A1 (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
TWI381848B (zh) * | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
MX349210B (es) | 2009-06-03 | 2017-07-18 | Immunogen Inc | Métodos de conjugación. |
WO2011104731A1 (en) * | 2010-02-26 | 2011-09-01 | Decode Genetics Ehf | Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment |
CN103619357A (zh) | 2011-03-29 | 2014-03-05 | 伊缪诺金公司 | 用于制造具有改善的同质性的缀合物的方法 |
AU2012236398B2 (en) | 2011-03-29 | 2016-02-11 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
SG11201402887SA (en) * | 2011-12-08 | 2014-07-30 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
WO2014055842A1 (en) * | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9415118B2 (en) * | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
-
2014
- 2014-12-05 TW TW103142504A patent/TWI541022B/zh not_active IP Right Cessation
- 2014-12-11 WO PCT/US2014/069720 patent/WO2015094900A1/en active Application Filing
- 2014-12-11 TN TN2016000204A patent/TN2016000204A1/en unknown
- 2014-12-11 EA EA201691053A patent/EA201691053A1/ru unknown
- 2014-12-11 CA CA2930599A patent/CA2930599A1/en not_active Abandoned
- 2014-12-11 PE PE2016000802A patent/PE20160994A1/es not_active Application Discontinuation
- 2014-12-11 AP AP2016009271A patent/AP2016009271A0/en unknown
- 2014-12-11 US US14/567,063 patent/US9375488B2/en not_active Expired - Fee Related
- 2014-12-11 MX MX2016008072A patent/MX2016008072A/es unknown
- 2014-12-11 AU AU2014366359A patent/AU2014366359A1/en not_active Abandoned
- 2014-12-11 BR BR112016013026A patent/BR112016013026A2/pt not_active Application Discontinuation
- 2014-12-11 EP EP14824266.2A patent/EP3082873A1/en not_active Withdrawn
- 2014-12-11 SG SG11201604119YA patent/SG11201604119YA/en unknown
- 2014-12-11 KR KR1020167015963A patent/KR101708603B1/ko active IP Right Grant
- 2014-12-11 NZ NZ719936A patent/NZ719936A/en not_active IP Right Cessation
- 2014-12-11 CN CN201480069206.8A patent/CN105916523A/zh active Pending
- 2014-12-11 JP JP2016548365A patent/JP6113933B1/ja not_active Expired - Fee Related
-
2016
- 2016-05-04 IL IL245483A patent/IL245483A0/en unknown
- 2016-06-15 CL CL2016001496A patent/CL2016001496A1/es unknown
- 2016-06-17 PH PH12016501185A patent/PH12016501185A1/en unknown
- 2016-10-27 HK HK16112380.5A patent/HK1224179A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160074679A (ko) | 2016-06-28 |
KR101708603B1 (ko) | 2017-02-20 |
US9375488B2 (en) | 2016-06-28 |
WO2015094900A1 (en) | 2015-06-25 |
TN2016000204A1 (en) | 2017-10-06 |
PH12016501185A1 (en) | 2016-07-25 |
AP2016009271A0 (en) | 2016-06-30 |
TWI541022B (zh) | 2016-07-11 |
CL2016001496A1 (es) | 2017-06-23 |
SG11201604119YA (en) | 2016-07-28 |
JP6113933B1 (ja) | 2017-04-12 |
PE20160994A1 (es) | 2016-10-08 |
MX2016008072A (es) | 2017-03-27 |
AU2014366359A1 (en) | 2016-05-26 |
JP2017511792A (ja) | 2017-04-27 |
HK1224179A1 (zh) | 2017-08-18 |
TW201526914A (zh) | 2015-07-16 |
EP3082873A1 (en) | 2016-10-26 |
US20150165067A1 (en) | 2015-06-18 |
CA2930599A1 (en) | 2015-06-25 |
CN105916523A (zh) | 2016-08-31 |
NZ719936A (en) | 2017-05-26 |
BR112016013026A2 (pt) | 2017-09-26 |
IL245483A0 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691053A1 (ru) | Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии | |
EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
CY1122161T1 (el) | Συζευγμενα αντισωματα anti-cd38 | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
EA201390642A1 (ru) | Цитотоксические агенты, содержащие новые производные анзамитоцина | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
EA201590207A1 (ru) | Композиции и способы регуляции car-т-клеток | |
EA201590987A1 (ru) | Соединения и способы их применения | |
EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
EA201591404A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
EA201591825A1 (ru) | Антагонизм миостатина у субъектов - людей | |
MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
TR201904980T4 (tr) | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. | |
CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа |